Literature DB >> 19368367

Identification of advanced reaction products originating from the initial 4-oxo-2-nonenal-cysteine Michael adducts.

Yuuki Shimozu1, Takahiro Shibata, Makoto Ojika, Koji Uchida.   

Abstract

4-Oxo-2-nonenal (ONE), an aldehyde originating from the peroxidation of omega6 polyunsaturated fatty acids, preferentially reacts with the cysteine residues of protein. Despite the fact that there has been significant recent interest in the protein reactivity and biological activity of ONE, the structural basis of the ONE-cysteine adducts remain to be established. In the present study, to gain a structural insight into the sulfhydryl modification by ONE, we characterized reaction products that originated from the initial ONE-cysteine Michael adducts. N-Acetyl-L-cysteine (10 mM) was incubated with an equimolar concentration of ONE in 0.1 M phosphate buffer (pH 7.4) at 37 degrees C. Within 1 h of incubation, the reaction of N-acetyl-L-cysteine with ONE resulted in the formation of two (C-2 and C-3) Michael addition products possessing a carbonyl functionality. Subsequent incubation of the reaction mixture resulted in their disappearance and concomitant formation of advanced reaction products, including a minor product III and major products IVa, IVb, and V. Product III was identified to be a thiomorpholine derivative, 4-acetyl-5-hydroxyl-6-(2-oxoheptyl)thiomorpholine-3-carboxylic acid, which might have originated from the C-2 Michael addition product. The major products were identified to be the novel 2-cyclopentenone derivatives, that is, 2-(acetylamino)-3-[(3-butyl-4-oxocyclopent-2-en-1-yl)sulfanyl]propionic acid (IVa and its isomer IVb) and 2-(acetylamino)-3-[(4-butyl-5-oxocyclopent-3-en-1-yl)sulfanyl]propionic acid (V), which might be generated through the base-catalyzed cyclization of the C-2 and C-3 Michael addition products, respectively. The furan derivative, which has been reported as the end product of the Michael adducts, was found to be formed only under acidic conditions. Thus, this study identified the novel ONE-cysteine adducts, including the most prominent 2-cyclopentenone derivatives, that originated from the initial Michael adducts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368367     DOI: 10.1021/tx900059k

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  6 in total

1.  Scavenging 4-Oxo-2-nonenal.

Authors:  Venkataraman Amarnath; Kalyani Amarnath
Journal:  Chem Res Toxicol       Date:  2015-09-11       Impact factor: 3.739

2.  Synthesis of deuterium-labeled analogs of the lipid hydroperoxide-derived bifunctional electrophile 4-oxo-2(E)-nonenal.

Authors:  Jasbir S Arora; Tomoyuki Oe; Ian A Blair
Journal:  J Labelled Comp Radiopharm       Date:  2011-05-15       Impact factor: 1.921

3.  Identification of a lipid peroxidation product as the source of oxidation-specific epitopes recognized by anti-DNA autoantibodies.

Authors:  Natsuki Otaki; Miho Chikazawa; Ritsuko Nagae; Yuki Shimozu; Takahiro Shibata; Sohei Ito; Yoshinari Takasaki; Junichi Fujii; Koji Uchida
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

4.  Lipid peroxidation modification of protein generates Nepsilon-(4-oxononanoyl)lysine as a pro-inflammatory ligand.

Authors:  Takahiro Shibata; Yuuki Shimozu; Chika Wakita; Noriyuki Shibata; Makio Kobayashi; Sachiko Machida; Rina Kato; Hiroyuki Itabe; Xiaochun Zhu; Lawrence M Sayre; Koji Uchida
Journal:  J Biol Chem       Date:  2011-04-06       Impact factor: 5.157

5.  4-oxo-2-nonenal (4-ONE): evidence of transient receptor potential ankyrin 1-dependent and -independent nociceptive and vasoactive responses in vivo.

Authors:  Rabea Graepel; Elizabeth S Fernandes; Aisah A Aubdool; David A Andersson; Stuart Bevan; Susan D Brain
Journal:  J Pharmacol Exp Ther       Date:  2011-01-04       Impact factor: 4.030

6.  An apoptosis-associated mammary protein deficiency leads to enhanced production of IgM antibodies against multiple damage-associated molecules.

Authors:  Miho Chikazawa; Natsuki Otaki; Takahiro Shibata; Takehiko Yasueda; Tsukasa Matsuda; Koji Uchida
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.